Continuous subcutaneous levodopa/ carbidopa infusion for Parkinson's disease: 3-year data from the BeyoND study

被引：0
|
作者：
Poewe, W. [1 ]
Stocchi, F. [2 ]
Adar, L. [3 ]
Sopromadze, S. [3 ]
Yardeni, T. [3 ]
Giladi, N. [4 ]
机构：
[1] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria
[2] Univ & Inst Res & Med Care, IRCCS San Raffaele, Rome, Italy
[3] NeuroDerm Ltd, Rehovot, Israel
[4] Tel Aviv Univ, Neurol Inst, Sagol Sch Neurosci, Sackler Sch Med,Tel Aviv Med Ctr, Tel Aviv, Israel
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2023年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPR-282
引用
收藏
页码：313 / 313
页数：1
相关论文
共 50 条
  • [1] Continuous Subcutaneous Levodopa/Carbidopa Infusion with ND0612 For Parkinson's Disease: Three-year Data from the Openlabel BeyoND Study
    Poewe, W.
    Ellenbogen, A.
    Stocchi, F.
    Adar, L.
    Salin, L.
    Case, R.
    Yardeni, T.
    Giladi, N.
    MOVEMENT DISORDERS, 2023, 38 : S46 - S46
  • [2] Continuous subcutaneous levodopa-carbidopa infusion for Parkinson's disease
    Moes, Harmen R.
    Buskens, Erik
    van Laar, Teus
    LANCET NEUROLOGY, 2024, 23 (09): : 856 - 857
  • [3] Safety and Efficacy of Continuous Subcutaneous Levodopa/Carbidopa Infusion for Parkinson's disease: Three-Year Data from the Open-Label BeyoND study
    Ellenbogen, Aaron
    Adar, Liat
    Salin, Laurence
    Case, Ryan
    Yardeni, Tamar
    Espay, Alberto
    NEUROLOGY, 2023, 100 (17)
  • [4] Long-term, continuous, subcutaneous levodopa/carbidopa infusion with ND0612 in Parkinson's disease: 3-year outcomes from the open-label BeyoND study
    Ellenbogen, Aaron L.
    Poewe, Werner
    Espay, Alberto J.
    Simuni, Tanya
    Gurevich, Tanya
    Yardeni, Tami
    Lopes, Nelson
    Sasson, Nissim
    Case, Ryan
    Stocchi, Fabrizio
    BeyoND Study Grp
    PARKINSONISM & RELATED DISORDERS, 2025, 132
  • [5] Continuous subcutaneous levodopa-carbidopa infusion for Parkinson's disease Reply
    Espay, Alberto J.
    Rascol, Olivier
    LANCET NEUROLOGY, 2024, 23 (09): : 857 - 857
  • [6] CONTINUOUS SUBCUTANEOUS LEVODOPA/CARBIDOPA INFUSION WITH ND0612 FOR PARKINSON'S DISEASE: THREE-YEAR DATA FROM THE OPEN-LABEL BEYOND STUDY
    Stocchi, F.
    Poewe, W.
    Ellenbogen, A.
    Adar, L.
    Salin, L.
    Case, R.
    Yardeni, T.
    Giladi, N.
    PARKINSONISM & RELATED DISORDERS, 2024, 122
  • [7] Subcutaneous Levodopa Infusion for Parkinson's Disease: 1-Year Data from the Open-Label BeyoND Study
    Poewe, Werner
    Stocchi, Fabrizio
    Arkadir, David
    Ebersbach, Georg
    Ellenbogen, Aaron L.
    Giladi, Nir
    Isaacson, Stuart H.
    Kieburtz, Karl
    LeWitt, Peter
    Olanow, C. Warren
    Simuni, Tanya
    Thomas, Astrid
    Zlotogorski, Abraham
    Adar, Liat
    Case, Ryan
    Oren, Sheila
    Orenbach, Shir Fuchs
    Rosenfeld, Olivia
    Sasson, Nissim
    Yardeni, Tami
    Espay, Alberto J.
    MOVEMENT DISORDERS, 2021, 36 (11) : 2687 - 2692
  • [8] Continuous subcutaneous carbidopa improves levodopa pharmacokinetics in Parkinson's disease patients
    Caraco, Y.
    Giladi, N.
    Oren, S.
    LeWitt, P. A.
    MOVEMENT DISORDERS, 2012, 27 : S111 - S111
  • [9] Continuous infusion of levodopa-carbidopa intestinal gel in Parkinson's disease
    Guthikonda, Lalitha N.
    Lyons, Kelly E.
    Pahwa, Rajesh
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2014, 3 (04) : 331 - 333
  • [10] Levodopa Pharmacokinetics in Switching From Levodopa/Carbidopa Intestinal Gel to Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in a Patient With Parkinson's Disease: A Case Report
    Nukariya, Tomonori
    Tezuka, Toshiki
    Okusa, Shohei
    Okochi, Ryotaro
    Sakai, Yuto
    Nihei, Yoshihiro
    Nakahara, Jin
    Seki, Morinobu
    JOURNAL OF MOVEMENT DISORDERS, 2025,
12345